Fairvalue-Calculator Fairvalue-Calculator
EN DE

Vitasora Health Limited (VHL) Fair Value & Analysis

Healthcare · AU · Market cap A$19.4M

VH Vitasora Health Limited VHL · AU
PriceA$0.0130
Fair ValueA$0.0200
Upside+53.8%
Quality95/100
Evidence: Low Range A$0.0200 – A$0.0300

Fair value as of: Jun 24, 2026

From 2 valuation models · updated 6 days ago

Share price +10.0% over the past month.

Price vs Fair Value (12 months)

A$0.0508 A$0.0106 Fair Value A$0.0200 Jun 2025 Jun 2026

12‑month range A$0.0106 – A$0.0508 · fair‑value band A$0.0200 – A$0.0300 · the A$0.0130 price screens below the A$0.0200 fair value. As of Jun 24, 2026.

✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →

Analysis

Vitasora Health Limited (VHL) currently trades at A$0.0130, while our model-based Fair Value estimate is A$0.0200 — implying the stock looks roughly 53.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

Trailing-twelve-month revenue stands at A$5.0M. Revenue grew 84.5% year over year. Fundamentals as of Jun 24, 2026

Key figures & financial health

Revenue (TTM) A$5.0M
Revenue growth (YoY) +84.5%
Net margin -231%
Return on equity -106%
Free cash flow −A$9.2M FY2025
Operating margin -180%
More key figures
EPS (TTM) A$-0.0100
Net debt A$530K FY2024

Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.

About the company

Vitasora Health Limited researches, develops, and commercializes medical devices in Australia and the United States. It is also involved in the production of mobile health applications. The company was formerly known as Respiri Limited and changed its name to Vitasora Health Limited in April 2025. The company is headquartered in Melbourne, Australia.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Vitasora Health Limited reported revenue of A$3.7M in FY2025 versus A$270K in FY2021, a compound +92.5%/yr. Reported net income was −A$10.1M in FY2025.

Revenue +92.5%/yr
FY21 A$270K
FY22 A$254K
FY23 A$70.5K
FY24 A$457K
FY25 A$3.7M
Net income
FY21 −A$11.0M
FY22 −A$6.6M
FY23 −A$5.8M
FY24 −A$7.1M
FY25 −A$10.1M

Open the full interactive analysis →

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $153.16 $183.66 +20%
Pro Medicus Limited PME A$165.64 A$28.02 -83%
BrightSpring Health Services, Inc BTSG $60.59 $23.87 -61%
Tempus AI, Inc TEM $48.61 $12.67 -74%
HealthEquity, Inc HQY $86.03 $54.47 -37%
M3, Inc MTHRY $5.20 $5.32 +2%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is Vitasora Health Limited (VHL) undervalued?
As of Jun 24, 2026, our model estimates a fair value of A$0.0200 versus a price of A$0.0130 — about +54% (undervalued). Model-based estimate, not financial advice.
What is the fair value of VHL?
Our 21-model fair value for Vitasora Health Limited is A$0.0200 (as of Jun 24, 2026), built from audited fundamentals. The current price is A$0.0130.
What is the quality score of VHL?
Vitasora Health Limited has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of Vitasora Health Limited (VHL)?
Vitasora Health Limited reported trailing-twelve-month revenue of about A$5.0M (latest available figure, as of Jun 24, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.